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INTRODUCTION
Accurate diagnosis of lymph node metastasis is
very important in deciding the optimal treatment
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Abstract : Objectives : We evaluate whether integrated fluorodeoxyglucose-positron emis-
sion tomography and computed tomography (FDG-PET/CT) scan can diagnose the pres-
ence of lymph node metastasis more accurately than computed tomography (CT) scan
alone. Methods : Forty-two patients with lung cancer preoperatively underwent integrated
PET/CT scan using FDG and CT scan and underwent pulmonary resection and lymph
node dissection. We judged cases as lymph node metastasis if the lymph node visually
accumulated FDG at PET/CT scan and measured 1 cm or greater in the short axis at CT
scan. We retrospectively analyzed whether our judgments in each modality were consis-
tent with the pathological diagnosis. Results : Two-hundred and seventeen stations of
lymph node were dissected and 21 stations (9.7%) were histologically diagnosed as posi-
tive metastasis. Thirty-two stations of lymph node visually accumulated FDG at PET/CT
scan and 17 stations measured 1 cm or greater in the short axis at CT scan. Concerning
the diagnosis of lymph node metastasis, PET/CT scan showed significantly higher sensi-
tivity than CT scan (81% vs. 48%, p=0.024). The false-positive rate was significantly high
in PET-positive lymph nodes measuring less than 1 cm in diameter. There were 4 false-
negative lymph nodes with both scans. All of these were less than 7 mm in diameter and
had a low percentage of metastatic foci in the lymph node. Concerning the diagnosis of
N staging, there was no significant difference between PET/CT scan and CT scan (83%
vs. 69%, p=0.124). However, the identification of N2 disease at PET/CT scan was signifi-
cantly more accurate than that at CT scan (100% vs. 38%, p=0.031). Conclusions : PET/CT
is superior to CT scan in lymph node staging. However, because the false-positive rate is
high in PET-positive lymph nodes measuring less than 1 cm in diameter, we think that
clinical background should be considered and other modalities or histological examina-
tions should be undertaken if necessary. J. Med. Invest. 57 : 305-313, August, 2010
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of lung cancer. Recently, positron emission tomogra-
phy and computed tomography (PET/CT) scan has
been undertaken in many facilities and its efficacy
for the diagnosis of accurate staging of lung can-
cer has been reported (1-2). Gould MK. et al. (3)
reported that PET scan was significantly better than
computed tomography (CT) scan in a meta-analysis.
The PLUS multi-center randomized trial also proved
the effectiveness of PET scan in preoperative pa-
tients with suspected lung cancer (4). Subsequently,
Birm Ö et al. (5) reported the same results in a
meta-analysis and, recently, it has been indicated
that PET scan should be undertaken for patients
with lung cancer with regard to mediastinal and
extrathoracic staging, and it is recommended as
grade IB by a standardized method ‘Methodology
for Lung Cancer Evidence Review and Guideline
Development’ in the ACCP guidelines (6).
Since PET/CT scan was introduced in our facil-
ity in December 2005, we have used it for lung can-
cer patients to diagnose preoperative staging, recur-
rence, and to judge the effectiveness of induction
therapy. We retrospectively evaluated the effective-
ness of PET/CT scan for preoperative lymph node
staging for lung cancer patients compared with that
of CT scan.
MATERIALS AND METHODS
Patients
Between December 2005 and April 2007, 42 con-
secutive patients with a histologic diagnosis of lung
cancer, who underwent a curative operation at
Tokushima University Hospital, were retrospectively
reviewed. All patients preoperatively underwent both
integrated PET/CT scan using fluorodeoxyglucose
(FDG) and chest CT scan including chest X-ray and
brain MRI as well as operative indication being
assessed. The protocol of this study was not sub-
mitted to Institutional Review Board because FDG-
PET/CT scan and chest CT scan were routine pre-
operative examination and this study was retrospec-
tive one. The patients underwent pulmonary resec-
tion and lymph node dissection, which was a radi-
cal operation. None of the patients in the study re-
ceived preoperative chemotherapy or radiotherapy.
The histologic type of lung cancer was adenocarci-
noma in 30 patients, squamous cell carcinoma in 8,
large cell carcinoma in 1, small cell carcinoma in 2,
and pleomorphic carcinoma in 1. The pathologic N
stages were N0 in 32, N1 in 2, N2 in 8, and N3 in 0
(Table 1). The lymph nodes were classified accord-
ing to the original lymph node map of lung cancer
(7).
FDG-PET/CT scan protocol and image interpre-
tation
The patients were required to fast for 6 hours
and avoid strenuous work or exercise for 24 hours
before PET/CT scan. Sixty minutes after the intrave-
nous injection of FDG (3.7 MBq/kg body weight),
PET/CT scan was performed with an Aquiduo
(Toshiba Medical Systems, Tokyo, Japan). Patients
were imaged from the skull base to the mid-thigh
level. The technical parameters used for the CT scan
were a detector row configuration of 161.25 mm,
a helical pitch of 15, a gantry rotation speed of 0.5
s, peak voltage of 120 kVp, a tube load of 50 mA
and slice thickness of 2 mm. An emission scan was
acquired immediately following the CT scan for 2
min per bed position in 3D mode. The images were
usually reconstructed using ordered subset expec-
tation maximization selecting 4 iterations and 12
subsets, a 128128 matrix, and post-smoothing
with an 8 mm Gaussian filter. The reconstructed
Table 1. Characteristics of the patients
Variable Data
NO. of patients 42
Age (yrs) 68.09.5
Sex
Male 25
Female 17
Tumor location
Right upper lobe 14
Right middle lobe 4
Right lower lobe 9
Left upper lobe 5
Left lower lobe 10
Histology
Adenocarcinoma 30
Squamous cell carcinoma 8
Large cell carcinoma 1
Small cell carcinoma 2
Pleomorphic carcinoma 1
Pathologic N stage
N0 32
N1 2
N2 8
N3 0
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spatial resolution after smoothing was 9.2 mm.
Abnormal FDG uptake was defined as greater
than background activity in surrounding normal tis-
sue excluding physiologic uptake sites. Regions of
interest (ROI) were placed on visible uptake sites
and standardized uptake values (SUV) were calcu-
lated as
SUV=decay-corrected activity (kBq)/tissue volume
(ml)/injected-FDG activity (kBq)/body weight (g).
In this study, the maximum SUV was used to mini-
mize of partial volume effect and assure reproduci-
bility of measurements.
CT scan protocol and image interpretation
Multidetector CT scan was performed with an
Aquilion 16 (Toshiba Medical Systems, Tokyo,
Japan). The technical parameters used for the CT
scan were a detector row configuration of 160.5
mm, a helical pitch of 15, a gantry rotation speed
of 0.5 s, peak voltage of 120 kVp, and a tube load of
100-400 mA and slice thickness of 1 mm. The win-
dow level and width were set at -500 Hounsefield
units (HU), and 1500 HU.
Criteria of lymph node metastasis
We judged the lymph node station as metastasis
if FDG was visually accumulated greater than back-
ground activity in surrounding normal tissue ex-
cluding physiologic uptake sites at PET/CT scan.
At the same time, we measured the short-axis di-
ameter of the largest lymph node at its station. We
also judged the lymph node station as metastasis if
the short-axis diameter of the lymph node was
greater than 1 cm at axial view of CT scan as in pre-
vious reports (8, 9). Two chest surgeons HT and
KK analyzed PET/CT scan by consensus while re-
ferring to reports made by several experienced nu-
clear medicine physicians. Two chest surgeons HT
and KK also analyzed CT scan by consensus while
referring to reports made by several radiologists.
Discrepancies were resolved after consultation.
Histological Examination
The dissected lymph nodes were examined his-
tologically using formalin-fixed and paraffin-embed-
ded sections and the largest section in each lymph
node was cut and examined with hematoxylin and
eosin staining with a microscope.
Statistical Analysis
True-positive (TP), true-negative (TN), false-
positive (FP), and false-negative (FN) results of
PET/CT scan and CT scan for lymph node metas-
tasis were compared with the results of pathologic
diagnosis. Sensitivity was calculated as TP/TP+FN,
specificity as TN/TN+FP, positive predictive value
(PPV) as TP/TP+FP, negative predictive value
(NPV) as TN/TN+FN, and accuracy as TP+TN/
total. All data were analyzed for significance by the
2-tailed Student’s t test using the SPSS 11.0 for
Windows software (SPSS Japan Inc., Tokyo, Japan).
RESULTS
In the 217 dissected lymph node stations, 21 sta-
tions (9.7%) were histologically diagnosed as positive
metastasis. Thirty-two lymph node stations visually
accumulated FDG at PET/CT scan and the mean
value of maximum SUV of those lymph node sta-
tions was between 1.7 and 8.6 (meanSD, 3.7
1.6). PET/CT scan yielded TP in 17 lymph node
stations, FP in 15, FN in 4, and TN in 181 (Table 2).
Seventeen lymph node stations measured 1 cm or
greater in short axis at CT scan. This yielded TP
in 10, FP in 7, FN in 11, and TN in 189 (Table 2).
The sensitivity, specificity, accuracy, positive predic-
tive value, and negative predictive value of PET/CT
scan were 81%, 92%, 91%, 53%, and 98%, respectively,
whereas those of CT scan were 48%, 96%, 91%, 59%,
and 94% (Table 3). PET/CT scan showed signifi-
cantly higher sensitivity than CT scan (p=0.024).
Table 2. PET/CT and CT analysis with pathologic diagnosis
Variable With metastasis Without metastasis Total
PET/CT diagnosis
Positive 17 true-positive 15 false-positive 32
Negative 4 false-negative 181 true-negative 185
Total 21 196 217
CT diagnosis
Positive 10 true-positive 7 false-positive 17
Negative 11 false-negative 189 true-negative 200
Total 21 196 217
Table 3. Diagnostic results of PET/CT scan and CT scan
Variable PET/CT CT Difference
Sensitivity 0.81 0.48 P=.024
Specificity 0.92 0.96 0.08
Accuracy 0.91 0.91 0.86
Positive predictive value 0.53 0.59 0.93
Negative predictive value 0.98 0.94 0.15
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Table 4 shows a comparison of lymph node stag-
ing by PET/CT scan and CT scan with that by pa-
thologic lymph node staging. The accuracy of lymph
node staging was 83% at PET/CT scan and 69% at
CT scan (p=0.124). However, the identification of
N2 disease was 8 of 8 (100%) at PET/CT scan, but
3 of 8 (37.5%) at CT scan. We could diagnose the
N2 disease at PET/CT scan more accurately than
at CT scan (p=0.0031).
A representative case with a both PET and CT
true-positive result is shown in Figure 1. FDG was
accumulated in pretracheal lymph node (#3) at
PET/CT scan. The size and maximum SUV values
were 11.0 mm and 6.2. The lymph node was surgi-
cally dissected and diagnosed as metastasis.
There were 4 false-negative lymph nodes in 3
cases (Table 5). All of these measured less than 7
mm in diameter and showed small metastatic areas.
Table 4. Comparison of N staging with PET/CT scan and CT scan
PET/CT diagnosis CT diagnosis
N0 N1 N2 N3 Total N0 N1 N2 N3 Total
Pathologic N Stage
N0 26 2 4 0 32 25 5 2 0 32
N1 1 1 0 0 2 1 1 0 0 2
N2 0 0 8 0 8 4 1 3 0 8
N3 0 0 0 0 0 0 0 0 0 0
Total 27 3 12 0 42 30 7 5 0 42
Figure 1. Representative case of true-positive FDG-PET/CT scan and chest CT scan
A : Chest CT scan demonstrated the significant swelling of pretracheal lymph node (#3).
B : PET/CT scan demonstrated the accumulation of FDG (arrow) in the pretoracheal lymph node (#3).
C : The view of maximum intensity projection (MIP) of PET/CT scan demonstrated the accumulation of FDG in primary tumor and
mediastinal lymph nodes.
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A representative case with a PET false-negative re-
sult is shown in Figure 2. A 75-year-old male (pa-
tient 3 in Table 5) with squamous cell carcinoma
received preoperative PET/CT scan. FDG was not
accumulated in mediastinal and hilar lymph nodes
and clinical N-stage was diagnosed as N0. He un-
derwent surgical resection of the primary tumor and
lymph node dissection. Histopathologically, right hi-
lar lymph node station (#10) showed involvement
of tumor cells and pathological N-stage was diag-
nosed as N1. The size of the metastatic lymph node
was 7 mm in diameter and the metastatic foci occu-
pied less than 5% of the total in the largest section
of the lymph node.
There were 15 false-positive lymph nodes in 8
cases. They were 8 mediastinal and 7 hilar lymph
nodes. Median size of the lymph nodes was between
4.6 and 11.0 mm (meanSD, 7.51.9 mm). Maxi-
mum SUV was between 1.9 and 5.2 (meanSD,
3.41.6). Their histological characteristics were
lymphoid follicular hyperplasia with anthracosis,
calcification, and anthrasilicosis (Table 6). All 8
Table 5. False negative PET/CT findings
NO. Age/sex Histologic type Station and size The percentage of metastatic area inlargest section of the lymph node
1 69/male Ad #3/5.4 mm 1%
2 31/female Sq #5/4.8 mm 20%
#10/5.0 mm 60%
3 76/male Sq #10/7.0 mm 5%
Ad=Adenocarcinoma, Sq=Squamous cell carcinoma
#3=Pretracheal lymph nodes, #5=Subaortic lymph nodes, #10=Hilar lymph nodes
Figure 2. Representative case of false-negative FDG-PET/CT scan
A : FDG was not accumulated in the hilar lymph node (#10) at PET/CT scan.
B : Microscopic appearance of lymph nodes (hematoxylin and eosin staining, original magnification100). A few tumor cells (arrow)
were recognized in the largest section of the lymph node.
C : The view of maximum intensity projection (MIP) of PET/CT scan demonstrated no accumulation of FDG in the mediastinal and
hilar lymph nodes.
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cases with false-positive results on FDG-PET/CT
scan had smoking history (B.I.=300-4600), 2 cases
(25.0%) had silicosis, and one case (12.5%) had had
tuberculosis in the past. A representative case with
a PET false-positive result is shown in Figure 3.
A 69-year-old male (patient 8 in Table 6) with adeno-
carcinoma received preoperative PET/CT scan.
FDG was accumulated in mediastinal and hilar
lymph node stations (#3, #7, #10, #11) clinical N-
stage was diagnosed as N2. Sizes and maximum
Figure 3. Representative case of false-positive FDG-PET/CT scan
A : PET/CT scan demonstrated accumulation of FDG (arrow) in the subcarinal lymph node (#7).
B : Microscopic appearance of lymph nodes (hematoxylin and eosin staining, original magnification100). Follicular lymphoid hy-
perplasia with anthrasilicosis and no tumor cells in the lymph nodes were revealed.
C : The view of maximum intensity projection (MIP) of PET/CT scan demonstrated the accumulation of FDG in primary tumor and
mediastinal and hilar lymph nodes.
Table 6. False positive PET/CT findings
No. Age/sex Station and size Maximum SUV Histologial findings of lymph node Past history B.I.
1 56/male #11/11.0 mm 5.2 anthracosis 630
2 65/male #3/6.7 mm 3.1 anthrasilicosis Silicosis 4600
#11/6.8 mm 3.6 anthrasilicosis
3 69/male #11/5.0 mm 3.1 anthracosis 800
4 69/male #11/9.7 mm 3.1 anthracosis 1820
5 67/male #3/9.5 mm 2.8 anthracosis 640
#7/6.2 mm 3.2 anthracosis
6 64/male #5/6.0 mm 3.5 anthrasilicosis Silicosis 740
#11/6.8 mm 8.6 anthrasilicosis
7 71/female #5/7.3 mm 2.6 anthrasilicosis 300
#6/6.7 mm 2.6 anthrasilicosis
8 69/male #3/7.2 mm 1.9 anthracosis, calcification Tuberculosis 800
#7/4.6 mm 2.4 anthracosis, calcification
#10/8.6 mm 2.3 anthracosis, calcification
#11/9.7 mm 2.4 anthracosis, calcification
#3=Pretracheal lymph nodes, #5=Subaortic lymph nodes, #6=Paraaortic lymph nodes
#7=Subcarinal lymph nodes, #10=Hilar lymph nodes, #11=Interlobar lymph nodes
B.I.=Brinkman Index
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SUV values of the lymph nodes (#7) were 4.6 mm
in diameter and 2.4. But because the degree of ac-
cumulation of FDG in each lymph node station was
almost same compared with background activity
in surrounding normal tissue in the view of maxi-
mum intensity projection (MIP), the possibility of
the N0 disease was suggested. He underwent sur-
gical resection of the primary tumor and lymph node
dissection. Histopathologically, dissected lymph
nodes showed follicular lymphoid hyperplasia with
anthrasilicosis and no involvement of tumor cells ;
pathological N-stage was diagnosed as N0.
Figure 4 shows the relationship between metas-
tatic states and the size of PET-positive lymph
nodes. If the cut-off value of the size of lymph nodes
was set at 1 cm in diameter, 9 (90%) of 10 lymph
node stations with PET-positive lymph nodes of
more than 1 cm showed metastasis. However, me-
tastasis was shown in only 8 (36%) of 22 lymph node
stations with PET-positive lymph nodes of less than
1 cm. The positive predictive value of lymph nodes
measuring more than 1 cm in diameter was signifi-
cantly higher than that of lymph nodes measuring
less than 1 cm in diameter (0.90 vs. 0.36, p=0.015).
DISCUSSION
In this study, the sensitivity of PET/CT scan was
significantly higher than that of only CT scan (81%
vs. 48%, p=0.024). On the other hand, the specificity
and accuracy of both modalities were similar. Con-
cerning lymph node staging, there were no signifi-
cant differences between FDG-PET/CT scan and
CT scan. However, concerning the identification of
N2 disease, which has sometimes been a clinical
problem of therapeutic strategy, FDG-PET/CT scan
was significantly more accurate than CT scan.
Many authors have reported that FDG-PET/CT
scan was effective with regard to lymph node stag-
ing in patients with lung cancer and the sensitivity
and specificity were almost 80-90% and were gener-
ally superior to those of CT scan (1-6, 9). Our data
was similar to previous reports and the sensitivity
of PET/CT scan was significantly superior to CT
scan although there was no difference between
FDG-PET/CT scan and CT scan with regard to
the specificity. It is recommended that FDG-PET/
CT scan should be performed as a non-invasive di-
agnostic tool in ACCP guidelines (5) and ESTS
guidelines (10). In view of our data, it is thought
that the FDG-PET/CT scan is currently the most
reliable non-invasive diagnostic tool with regard to
the presence of lymph node metastasis and should
be performed preoperatively as a routine examina-
tion.
In this study, the PPV of FDG-PET/CT scan was
53%. There were 8 cases with 15 false-positive
lymph node stations at FDG-PET/CT scan. All false-
positive lymph nodes showed lymphoid follicular hy-
perplasia with anthracosis, anthrasilicosis, and cal-
cification histologically. In addition, all patients with
false-positive lymph node stations were smokers.
Several previous studies have reported that the
causes of false-positive accumulation of FDG in
lymph nodes may be the infiltration of activated
macrophages and inflammatory cells in conditions
such as active tuberculosis and granuloma (11-13).
Lymphoid follicular hyperplasia is a type of chronic
lymphadenopathy and Chung JH et al. (14) reported
that the overexpression of glucose transporter 1
(Glut 1), which is known to be related to FDG up-
take, was recognized in lymph nodes with the find-
ing of lymphoid follicular hyperplasia. Therefore,
some authors mentioned that the presence of lym-
phoid follicular hyperplasia was possibly related to
false-positive results on FDG-PET/CT scan (14,
15). Chung JH et al. (14) also mentioned that pa-
tients with heavy smoking, chronic airway disease,
or tuberculosis might have mediastinal lymphoid
follicular hyperplasia. This would be compatible with
our findings because our cases with false-positive
Figure 4. The relationships between metastatic state and the
size of lymph nodes at
FDG-PET/CT scan. The positive predictive value of lymph nodes
of more than 1 cm in diameter was higher than that of those of
less than 1 cm in diameter (0.90 vs. 0.36, p=0.015).
True-positive cases False-positive cases
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results on FDG-PET/CT scan had a smoking his-
tory and concomitant lung diseases such as silico-
sis and previous pulmonary tuberculosis. In our
cases, if false-positive cases with those factor were
excluded, The specificity, accuracy, positive predic-
tive value of PET/CT scan were 98%, 97% and 85%
and they were more higher. Furthermore the accu-
racy of PET/CT scan was also significantly higher
than that of CT scan (p=0.023). So we have to judge
the findings of PET/CT scan in consideration of
clinical background.
Our study suggested that the PPV of lymph nodes
measuring more than 1 cm in diameter was signifi-
cantly higher than that of those measuring less than
1 cm in diameter. Therefore, if there is accumula-
tion of FDG in lymph nodes of more than 1 cm, we
will be able to diagnose metastasis at a high rate.
However, if there is accumulation of FDG in lymph
nodes measuring less than 1 cm, invasive modali-
ties such as mediastinoscopy, endobronchial ultra-
sonography transbronchial needle aspiration (EBUS-
TBNA), esophageal endoscopic ultrasound-guided
fine needle aspiration (EUS-FNA), and video-as-
sisted thoracic surgery (VATS) should be consid-
ered to decide the indication for curative operation
(16).
The negative predictive value (NPV) of FDG-
PET/CT scan was high. However, it is difficult to
diagnose as false-negative for lymph nodes in which
FDG is not found to have accumulated at PET/CT
scan. In our false-negative cases, the sizes of these
lymph nodes were small, less than 7 mm in diame-
ter, or a small metastatic area in the lymph node
was histologically identified. As they were inciden-
tal lymph node metastases, we could not preopera-
tively diagnose the presence of metastasis. There-
fore, there are limitations of the diagnostic capac-
ity of FDG-PET/CT scan especially in cases with
micrometastasis and small lymph nodes. If FDG
was not found to have accumulated in the lymph
nodes at PET/CT scan, we should diagnose as cN0
and make the decision on therapeutic principle. If
incidental lymph node metastases of N1 or N2 sta-
tion are found on final pathology examination of the
resected specimen, we should treat by using surgi-
cal resection followed by adjuvant chemotherapy
(17).
In conclusion, FDG-PET/CT scan is more ac-
curate than CT scan concerning the diagnosis of
lymph node metastasis and staging. However, we
have to judge the findings in consideration of clini-
cal background because false-positive results on
FDG-PET/CT scan are often recognized. We should
recognize the limitations of the diagnostic capacity
of FDG-PET/CT and select an appropriate therapy.
When there is accumulation of FDG in lymph nodes
of more than 1 cm in diameter, we should judge as
true-positive and decide the appropriate therapeu-
tic strategy. When there is accumulation of FDG
in the lymph nodes of less than 1 cm in diameter,
we have to make their histological diagnoses us-
ing EBUS-TBNA, EUS-FNA, mediastinoscopy and
VATS if we are obliged to change our therapeutic
strategy by the presence of metastasis. When there
is no accumulation of FDG in lymph nodes, we
should judge as true-negative and consider the sur-
gical approach.
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